Design Therapeutics Inc
NASDAQ:DSGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Robit Oyj
OMXH:ROBIT
|
FI |
|
A
|
Augwind Energy Tech Storage Ltd
TASE:AUGN
|
IL |
|
Highpeak Energy Inc
NASDAQ:HPK
|
US |
|
M
|
MGO Global Inc
NASDAQ:MGOL
|
US |
|
U
|
Unfold vc Asi SA
WSE:UNF
|
PL |
|
I
|
Inhome Prime Properties Socimi SA
MAD:YIPP
|
ES |
|
T
|
TeamViewer SE
XBER:TMV
|
DE |
|
M
|
Movie Games SA
WSE:MOV
|
PL |
|
Genuine Parts Co
NYSE:GPC
|
US |
|
G
|
Graphite Design Inc
TSE:7847
|
JP |
|
Frasers Logistics & Commercial Trust
SGX:BUOU
|
SG |
|
Lida Holdings Ltd
TWSE:4552
|
CN |
|
Asahi Group Holdings Ltd
TSE:2502
|
JP |
|
Agile Group Holdings Ltd
HKEX:3383
|
CN |
|
N
|
NBT Inc
KOSDAQ:236810
|
KR |
|
Sunopta Inc
F:ZSK
|
US |
|
K
|
Kasati JSC
VN:KST
|
VN |
|
O'Key Group SA
LSE:OKEY
|
LU |
|
T
|
Tan Chong Motor Holdings Bhd
KLSE:TCHONG
|
MY |
Design Therapeutics Inc
Research & Development
Design Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Design Therapeutics Inc
NASDAQ:DSGN
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Design Therapeutics Inc
Glance View
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.
